GAMMA Investing LLC Has $36.01 Million Stock Holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO)

GAMMA Investing LLC increased its stake in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 22,131.7% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 147,841 shares of the medical research company's stock after purchasing an additional 147,176 shares during the period. GAMMA Investing LLC owned approximately 0.53% of Bio-Rad Laboratories worth $36,008,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. Strategic Financial Concepts LLC bought a new stake in shares of Bio-Rad Laboratories in the fourth quarter valued at about $3,561,000. Lecap Asset Management Ltd. acquired a new stake in Bio-Rad Laboratories in the 4th quarter valued at approximately $510,000. LPL Financial LLC lifted its stake in Bio-Rad Laboratories by 34.3% in the 4th quarter. LPL Financial LLC now owns 5,195 shares of the medical research company's stock valued at $1,707,000 after acquiring an additional 1,326 shares in the last quarter. Blackhawk Capital Partners LLC. boosted its position in Bio-Rad Laboratories by 190.5% during the 4th quarter. Blackhawk Capital Partners LLC. now owns 2,176 shares of the medical research company's stock worth $715,000 after acquiring an additional 1,427 shares during the last quarter. Finally, O Shaughnessy Asset Management LLC acquired a new position in Bio-Rad Laboratories during the 4th quarter worth approximately $245,000. Institutional investors own 65.24% of the company's stock.

Bio-Rad Laboratories Stock Up 0.5%

BIO traded up $1.03 during trading on Friday, reaching $220.34. 88,469 shares of the stock were exchanged, compared to its average volume of 323,956. The company has a debt-to-equity ratio of 0.18, a quick ratio of 4.85 and a current ratio of 6.48. The stock's 50 day moving average price is $236.93 and its two-hundred day moving average price is $286.31. Bio-Rad Laboratories, Inc. has a twelve month low of $211.43 and a twelve month high of $387.99. The stock has a market cap of $6.00 billion, a P/E ratio of -3.39 and a beta of 0.93.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The medical research company reported $2.54 earnings per share for the quarter, topping the consensus estimate of $1.73 by $0.81. Bio-Rad Laboratories had a negative net margin of 71.86% and a positive return on equity of 3.90%. The company had revenue of $585.40 million for the quarter, compared to analyst estimates of $573.01 million. During the same period in the previous year, the business earned $2.30 EPS. Bio-Rad Laboratories's revenue for the quarter was down 4.2% compared to the same quarter last year. Equities analysts expect that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current year.

Analyst Ratings Changes

A number of analysts have recently issued reports on the stock. UBS Group lowered their price objective on shares of Bio-Rad Laboratories from $355.00 to $310.00 and set a "buy" rating on the stock in a report on Friday, May 2nd. Wall Street Zen raised shares of Bio-Rad Laboratories from a "hold" rating to a "buy" rating in a research report on Saturday, May 31st. Wells Fargo & Company cut their price target on shares of Bio-Rad Laboratories from $320.00 to $270.00 and set an "equal weight" rating on the stock in a research report on Thursday, April 17th. Royal Bank of Canada decreased their price objective on Bio-Rad Laboratories from $409.00 to $392.00 and set an "outperform" rating for the company in a report on Friday, May 2nd. Finally, Citigroup lowered their target price on Bio-Rad Laboratories from $400.00 to $350.00 and set a "buy" rating on the stock in a research report on Friday, May 2nd. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $330.50.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.